Immunic (NASDAQ:IMUX) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Immunic (NASDAQ:IMUX) released its quarterly earnings data on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.05, Zacks reports.

Immunic Price Performance

Shares of Immunic stock traded down $0.04 on Thursday, reaching $0.72. The company had a trading volume of 910,824 shares, compared to its average volume of 1,287,352. The firm has a market cap of $70.83 million, a price-to-earnings ratio of -0.77 and a beta of 1.53. The firm’s 50-day moving average price is $0.83 and its two-hundred day moving average price is $0.87. Immunic has a 1 year low of $0.56 and a 1 year high of $1.42.

Wall Street Analysts Forecast Growth

Several research analysts have commented on IMUX shares. Chardan Capital started coverage on Immunic in a research report on Monday, September 29th. They set a “buy” rating and a $13.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Immunic in a research note on Friday, September 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, October 8th. LADENBURG THALM/SH SH raised Immunic to a “strong-buy” rating in a report on Thursday, October 16th. Finally, Roth Capital started coverage on shares of Immunic in a report on Friday, November 7th. They issued a “buy” rating and a $3.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.80.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Immunic stock. Vanguard Group Inc. increased its holdings in shares of Immunic, Inc. (NASDAQ:IMUX) by 5.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 4,345,105 shares of the company’s stock after acquiring an additional 219,957 shares during the period. Vanguard Group Inc. owned about 4.40% of Immunic worth $3,832,000 at the end of the most recent quarter. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.